AU2006311433B2 - Alpha-helix mimetics and method relating to the treatment of cancer stem cells - Google Patents

Alpha-helix mimetics and method relating to the treatment of cancer stem cells Download PDF

Info

Publication number
AU2006311433B2
AU2006311433B2 AU2006311433A AU2006311433A AU2006311433B2 AU 2006311433 B2 AU2006311433 B2 AU 2006311433B2 AU 2006311433 A AU2006311433 A AU 2006311433A AU 2006311433 A AU2006311433 A AU 2006311433A AU 2006311433 B2 AU2006311433 B2 AU 2006311433B2
Authority
AU
Australia
Prior art keywords
cancer
alkyl
substituted
compound
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2006311433A
Other languages
English (en)
Other versions
AU2006311433A1 (en
Inventor
Michael Kahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Choongwae Pharmaceutical Co Ltd
Original Assignee
Choongwae Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Choongwae Pharmaceutical Co Ltd filed Critical Choongwae Pharmaceutical Co Ltd
Publication of AU2006311433A1 publication Critical patent/AU2006311433A1/en
Application granted granted Critical
Publication of AU2006311433B2 publication Critical patent/AU2006311433B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2006311433A 2005-11-08 2006-11-08 Alpha-helix mimetics and method relating to the treatment of cancer stem cells Active AU2006311433B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73465505P 2005-11-08 2005-11-08
US60/734,655 2005-11-08
PCT/US2006/043859 WO2007056593A2 (en) 2005-11-08 2006-11-08 α-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS

Publications (2)

Publication Number Publication Date
AU2006311433A1 AU2006311433A1 (en) 2007-05-18
AU2006311433B2 true AU2006311433B2 (en) 2012-06-28

Family

ID=37890190

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006311433A Active AU2006311433B2 (en) 2005-11-08 2006-11-08 Alpha-helix mimetics and method relating to the treatment of cancer stem cells

Country Status (8)

Country Link
US (2) US20070129353A1 (enExample)
EP (1) EP1957516B1 (enExample)
JP (1) JP5536336B2 (enExample)
KR (1) KR101486490B1 (enExample)
AU (1) AU2006311433B2 (enExample)
CA (1) CA2629136C (enExample)
ES (1) ES2570994T3 (enExample)
WO (1) WO2007056593A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080657B2 (en) * 2001-10-12 2011-12-20 Choongwae Pharma Corporation Compounds of reverse turn mimetics and the use thereof
US7566711B2 (en) * 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7232822B2 (en) * 2001-10-12 2007-06-19 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7576084B2 (en) * 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7671054B1 (en) 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
JP2009538903A (ja) * 2006-05-30 2009-11-12 チュンウェ ファーマ コーポレーション 幹細胞分化の誘導または抑制のための組成物
EP2783700A1 (en) * 2006-09-07 2014-10-01 Stemline Therapeutics, Inc. Cancer stem cell-targeted cancer therapy
AU2008325219A1 (en) * 2007-11-05 2009-05-14 Puretech Ventures Methods, kits, and compositions for administering pharmaceutical compounds
RU2512538C2 (ru) 2008-06-06 2014-04-10 Присм Байолэб Корпорейшн Альфа-спиральные миметики и способы, связанные с ними
WO2010001989A1 (ja) * 2008-07-03 2010-01-07 協和発酵キリン株式会社 癌幹細胞及び／または癌前駆細胞の減少剤並びに癌の再発及び／または転移の予防剤
US20100022549A1 (en) * 2008-07-23 2010-01-28 The Scripps Research Institute Alpha-helix mimetic with functionalized pyridazine
JP5816087B2 (ja) * 2008-08-29 2015-11-18 エンメエッセディ・イタリア・エッセ・エッレ・エッレ Ｓｍｏアンタゴニストとしての飽和二環式複素環誘導体
WO2010030948A2 (en) * 2008-09-12 2010-03-18 The Board Of Trustees Of The Leland Stanford Junior University Hedgehog signaling and cancer stem cells in hematopoietic cell malignancies
US8691819B2 (en) 2008-10-14 2014-04-08 Prism Biolab Corporation Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions
AU2010237633B2 (en) * 2009-04-15 2015-09-17 Jw Pharmaceutical Corporation Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof
EP2427451B1 (en) 2009-05-07 2019-03-20 PRISM BioLab Co., Ltd. Alpha helix mimetics and methods relating thereto
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
JPWO2011096440A1 (ja) 2010-02-03 2013-06-10 株式会社 ＰＲＩＳＭ ＢｉｏＬａｂ 天然変性タンパク質に結合する化合物およびそのスクリーニング方法
US20130231385A1 (en) 2010-05-28 2013-09-05 The Board Of Regents Of The University Of Texas Systems Oligo-benzamide compounds and their use
KR101892575B1 (ko) 2010-10-14 2018-08-31 제이더블유중외제약 주식회사 리버스-턴 유사체의 신규한 화합물 및 그 제조방법과 용도
JP2014500275A (ja) 2010-12-06 2014-01-09 フォリカ，インコーポレイテッド 禿頭症を治療するため、および毛髪の成長を促進するための方法
JP2014509298A (ja) 2011-02-25 2014-04-17 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ アルファへリックスミメティック及びその関連の方法
WO2012168167A1 (en) 2011-06-09 2012-12-13 F. Hoffmann-La Roche Ag Method for differentiation of pluripotent stem cells into vascular bed cells
US8835493B2 (en) 2011-11-23 2014-09-16 Board Of Regents, The University Of Texas System Oligo-benzamide compounds for use in treating cancers
US8754124B2 (en) 2011-11-23 2014-06-17 Board Of Regents, The University Of Texas System Oligo-benzamide compounds and their use in treating cancers
CN105899211A (zh) 2013-10-18 2016-08-24 小路弘行 使用cbp/连环蛋白的抑制剂治疗肝纤维化
EP3150207B1 (en) 2014-03-28 2019-12-25 National University Corporation Tottori University Inhibitory effect of low molecular weight compound on cancer and fibrosis
CA2988707C (en) * 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
GB201617630D0 (en) * 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
GB201617627D0 (en) * 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
US10961534B2 (en) 2018-07-13 2021-03-30 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating porphyria
EP3841197A1 (en) 2018-08-21 2021-06-30 F. Hoffmann-La Roche AG Methods for assessing transendothelial barrier integrity
EP3867358A1 (en) 2018-10-19 2021-08-25 F. Hoffmann-La Roche AG Synergistic transcription factors to induce high resistance transendothelial barrier
CN114727974A (zh) 2019-07-30 2022-07-08 艾科尼佐治疗股份有限公司 Hdac6抑制剂及其用途
AU2021358007A1 (en) * 2020-10-05 2023-06-01 Genesis Molecular Technologies, Inc. Topical agents for dermatological applications
WO2022169985A1 (en) 2021-02-03 2022-08-11 Eikonizo Therapeutics, Inc. Hdac6 inhibitors and uses thereof
AU2023250964A1 (en) 2022-04-08 2024-11-07 Eikonizo Therapeutics, Inc. Oxadiazole hdac6 inhibitors and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016135A2 (en) * 1999-09-01 2001-03-08 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US20050004131A1 (en) * 2003-02-13 2005-01-06 Aventis Pharma Deutschland Gmbh Substituted hexahydropyrazino (1,2-a) pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5929237A (en) * 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US6184223B1 (en) * 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US7008941B2 (en) * 2001-05-16 2006-03-07 Myriad Genetics, Inc. Reverse-turn mimetics and methods relating thereto
US7232822B2 (en) 2001-10-12 2007-06-19 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US20040072831A1 (en) * 2001-10-12 2004-04-15 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7576084B2 (en) 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
ATE398129T1 (de) * 2001-10-12 2008-07-15 Choongwae Pharma Corp Reverse-turn-mimetika und diese betreffendes verfahren
US7566711B2 (en) 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7671054B1 (en) 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
WO2004035587A1 (en) * 2002-10-17 2004-04-29 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
ATE472548T1 (de) 2003-02-13 2010-07-15 Sanofi Aventis Deutschland Substituierte hexahydro-pyrazino(1,2-a)pyrimidin- 4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2005021025A2 (en) * 2003-08-28 2005-03-10 Choongwae Pharma Corporation MODULATION OF β-CATENIN/TCF ACTIVATED TRANSCRIPTION
US7563825B1 (en) 2005-03-18 2009-07-21 Choongwae Pharma Corporation Modulation of beta-catenin coactivator interactions to effect stem cell growth or differentiation
AU2006227776A1 (en) * 2005-03-18 2006-09-28 Institute For Chemical Genomics Alpha-helix mimetics and methods relating to the treatment of fibrosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016135A2 (en) * 1999-09-01 2001-03-08 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US20050004131A1 (en) * 2003-02-13 2005-01-06 Aventis Pharma Deutschland Gmbh Substituted hexahydropyrazino (1,2-a) pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Vojkovsky, T., et al. Journal of Organic Chemistry. 1998, vol. 63, pages 3162-3163 *

Also Published As

Publication number Publication date
AU2006311433A1 (en) 2007-05-18
US20070129353A1 (en) 2007-06-07
CA2629136C (en) 2016-03-08
KR20080070060A (ko) 2008-07-29
KR101486490B1 (ko) 2015-01-27
US20100069333A1 (en) 2010-03-18
CA2629136A1 (en) 2007-05-18
WO2007056593A3 (en) 2007-07-12
WO2007056593A2 (en) 2007-05-18
ES2570994T3 (es) 2016-05-23
JP5536336B2 (ja) 2014-07-02
EP1957516B1 (en) 2016-03-09
EP1957516A2 (en) 2008-08-20
US8293743B2 (en) 2012-10-23
JP2009515890A (ja) 2009-04-16

Similar Documents

Publication Publication Date Title
EP1957516B1 (en) Alfa-helix mimetics and method relating to the treatment of cancer stem cells
CN114341162B (zh) 作为治疗剂的细胞毒素的肽缀合物
AU2002348649B2 (en) Reverse-turn mimetics and method relating thereto
US20080171745A1 (en) Methods relating to the treatment of fibrosis
KR101257824B1 (ko) 리버스-턴 유사체 및 이와 관련된 방법
CA2903107C (en) Coumarin derivatives and methods of use in treating hyperproliferative diseases
US20080242669A1 (en) Methods relating to the treatment of fibrotic disorders
JPS63295588A (ja) 生理活性物質ｋ−２５２の誘導体
CZ113692A3 (en) Quinoxalines, process of their preparation and their use
CN107531683A (zh) Usp7抑制剂化合物及使用方法
US6365617B1 (en) Indole and indazole urea-peptoids as thrombin receptor antagonists
US6369070B1 (en) Methods for inhibiting mrp1
US20240189304A1 (en) Bet protein inhibitors and use thereof
CN109384793A (zh) 一种具有hdac6抑制活性的硫醇类化合物及其应用
KR20190028769A (ko) 항종양 활성을 갖는 벤조-n-하이드록시 아미드 화합물
CN116887836A (zh) 用于治疗癌症的metap2抑制剂和cdk4/6抑制剂的组合

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)